Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences, Inc. filed a Form S-3 shelf registration that includes a sales agreement prospectus supplement to sell up to
The registration statement establishes a base prospectus permitting the company to offer various securities (common stock, preferred stock, debt, warrants and units) on a continuous or delayed basis under separate prospectus supplements. The sales agreement supplement governs the mechanics of at‑the‑market offerings under the Jefferies arrangement and sales may commence
MBX Biosciences is a clinical-stage biopharmaceutical company developing precision peptide therapies for endocrine and metabolic disorders using its proprietary Precision Endocrine Peptide (PEP™) platform. The company engineers long-acting peptide prodrugs with extended time-action profiles and low peak-to-trough ratios for less frequent dosing and potentially better tolerability.
Lead program canvuparatide (MBX 2109) targets chronic hypoparathyroidism with once-weekly parathyroid hormone replacement and has shown positive Phase 2 results; a Phase 3 trial is planned for the third quarter of 2026. Obesity candidate MBX 4291, a GLP‑1/GIP co-agonist prodrug, is in a Phase 1 trial and is designed for potential once-monthly dosing.
The company is also advancing imapextide (MBX 1416), a long-acting GLP‑1 receptor antagonist for post-bariatric hypoglycemia, now in a Phase 2a trial with topline results expected in the second quarter of 2026. MBX relies on third-party manufacturers, in-licenses key PEP™ intellectual property from Indiana University entities, and faces typical clinical, regulatory, funding and competitive risks highlighted in extensive risk factor disclosures.
MBX Biosciences reported a larger full-year 2025 net loss of
As of
MBX Biosciences reported a successful End-of-Phase 2 meeting with the FDA for once-weekly canvuparatide, clearing the way to start a Phase 3 trial in chronic hypoparathyroidism in Q3 2026. The double-blind, placebo-controlled study will enroll about 160 patients, randomizing them 3:1 to canvuparatide or placebo, with fixed-dose, titration and maintenance periods and a primary efficacy assessment at week 26.
The trial will track how many patients reach normal blood calcium while no longer needing conventional therapy, along with urinary calcium and other secondary measures, followed by an open-label extension. MBX also highlighted that canvuparatide has orphan drug designation from both the FDA and the European Medicines Agency for chronic hypoparathyroidism, supporting its continued development in the U.S. and Europe.
MBX Biosciences, Inc. director and President & CEO P. Kent Hawryluk reported exercising stock options into common stock. On February 26, 2026, he exercised options covering 28,768 shares, with the resulting common stock recorded at $16.00 per share.
After these transactions, his directly held common stock position is 728,274 shares, and directly held stock options total 91,668 shares underlying options. An additional 468,277 common shares are held indirectly by the P. Kent Hawryluk Revocable Trust, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
MBX Biosciences signed a lease for about 13,642 square feet of new office and lab space in Burlington, Massachusetts. The four-year lease is expected to start around May 1, 2026, with base rent of roughly $68,200 for the first twelve months and aggregate base rent of about $3.4 million, plus operating costs, taxes and utilities.
The company’s Chief Financial Officer, Richard Bartram, will resign effective March 15, 2026, then serve as a consultant to support the transition. He will receive severance under his employment agreement, extended option exercise rights, and a $13,400 lump sum related to COBRA premiums. John Smither, an experienced biotechnology finance executive, has been appointed Interim CFO with a part-time employment agreement that includes a $325,000 base salary, a target bonus equal to 40% of earned income, and a $25,000 sign-on bonus.
MBX Biosciences’ shareholder OrbiMed has updated its ownership position after recent share sales and dilution. OrbiMed Advisors LLC and affiliated funds now report beneficial ownership of 3,637,887 MBX common shares, representing 7.7% of the class based on 47,153,288 shares outstanding.
OrbiMed Capital GP VII LLC is general partner of OrbiMed Private Investments VII, LP, which holds 2,958,000 shares, or 6.3% of outstanding shares. OrbiMed Genesis GP LLC is general partner of OrbiMed Genesis Master Fund, L.P., which holds 679,887 shares, or 1.4% of outstanding shares.
The amendment notes OrbiMed’s percentage ownership fell by more than 1% due to an increase in MBX shares outstanding and reports multiple open-market sales by the Genesis and OPI VII funds in late
MBX Biosciences received an amended Schedule 13G/A reporting a significant institutional holding by Wellington-affiliated entities. Wellington Management Group LLP and related entities report beneficial ownership of 3,349,961 shares of MBX Biosciences common stock, representing 7.46% of the class as of 12/31/2025.
The shares are held of record by clients of Wellington investment advisers, which share voting and dispositive power over the securities. No single client is known to hold more than five percent of the class. Wellington certifies the position is held in the ordinary course of business and not to change or influence control.
MBX Biosciences, Inc. closed an at-the-market stock sale, issuing 2,250,986 shares of common stock at a volume weighted average price of $38.76 per share for gross proceeds of approximately $87.1 million. The shares were sold through Jefferies under an existing Open Market Sale Agreement and shelf registration on Form S-3.
The company currently plans to use the net proceeds to fund clinical-stage programs, discovery research and development, additional clinical development, and general corporate purposes including working capital and capital expenditures. MBX Biosciences may also use some proceeds and existing cash to in-license, acquire, or invest in complementary businesses or technologies, and still has capacity to sell up to an additional $62.9 million of common stock under the same program.
MBX Biosciences Chief Medical Officer Azoulay Salomon reported new equity compensation. On February 2, 2026, Salomon received 15,000 shares of common stock, representing a grant of restricted stock units that vest over four years in equal quarterly installments, conditioned on continued service.
On the same date, Salomon was also granted a stock option for 70,000 shares of common stock with an exercise price of